BioNTech SE (BNTX) Form 6-K — Oct 19, 2026
BioNTech SE (Nasdaq: BNTX) will present 16 abstracts spanning ten tumor types at the ESMO 2026 Congress in Madrid, October 23-27, 2026, covering its late-stage oncology pipeline in lung and breast cancer among other areas. The headline data are the first results from the global ROSETTA Lung-107 Phase 2 trial of pumitamig (PD-L1×VEGF-A bispecific) plus docetaxel in second-line metastatic NSCLC, selected for a late-breaking oral presentation, plus new Phase 2 data for the novel-novel combination of pumitamig with the B7-H3 ADC elfetabart drozuntecan in advanced solid tumors.
Key figures
- Abstracts
- 16
- Tumor Types
- 10
- Esmo Congress Dates
- October 23-27, 2026
- Ongoing Phase3 Trials
- 13
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.